Figure 1: design pHARM study

inclusion
- high risk patients:
  - 65+ years
  - polypharmacy
  - ATC A/ATC B
  - non-adherence

randomisation
- intervention group:
  - intervention GP
- control group:
  - control GP

Intervention period
- pharmaceutical anamnesis
  by the pharmacist
  t = 0
- pharmacotherapy review
  by the pharmacist
  t < 1 month
- pharmaceutical care plan
  by GP + pharmacist
  t < 1 month
- monitoring and follow up evaluation of pharmacotherapy
  by GP + pharmacist + practice nurse
  t = 3 months and t = 6 months

outcome
- Hospital Admissions Related to Medication (HARM)
- survival
- ADE (Adverse Drug Events)
- quality of life (EQ5D/Visual Analogue Scale)
  t = 12 months